Cardiovascular risk in various medical specialities. The results of the Russian multi-centre scientific and educational programme “Russian Doctors’ Health”

Aim. To assess the risk of fatal cardiovascular (CVD) events in medical doctors of various specialities, using modern risk scales, and to identify the target groups for primary prevention with a fixed-dose combination of enalapril / hydrochlorothiazide (HCT) and simvastatin. Material and methods. The programme included 12 non-teaching Russian hospitals and was divided into epidemiological, educational, therapeutic, and control phases. In 699 doctors, aged >40 years and representing 43 specialities (22,8% men; mean age 50,5±11,7 years), the risk of fatal CVD events and coronary events was assessed with SCORE and Framingham scales, respectively. All doctors were informed about their individual risk and target levels of risk factors (RFs), and also taught to self-control their blood pressure, physical activity, and body mass. In total, 287 doctors participated in the therapeutic phase (6 months): 52 were included in the antihypertensive therapy (AHT) group (enalapril/HCT); 38 – in the simvastatin group; and 197 – in the combined therapy group (AHT and simvastatin). Six months after the end of the therapeutic phase, the prevalence of continuing pharmaceutical and non-pharmaceutical primary prevention was analysed. Results. The prevalence of the main RFs was high: dyslipidemia was observed in 69,2% of the participants, AH – in 55,6%, abdominal obesity – in 34,5%, and smoking – in 14%. As many as 54,5% of the doctors had at least 3 RFs, while 25,8% had high SCORE-assessed risk, and 47,1% had indications for pharmaceutical primary prevention. The most adverse RF profile was registered in surgeons. Pharmaceutical primary prevention with a fixed-dose combination of enalapril/HCT and/or simvastatin significantly reduced both SCORE and Framingham risk levels. Six months after the therapeutic phase, 30,2% of the doctors stopped the treatment, and 37,2% continued pharmaceutical primary prevention. Conclusion. The results of the programme point to the high prevalence of modifiable RFs in middle-aged medical doctors. The data obtained could be a basis for the programs of primary CVD prevention.

1. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ 2004; 328: 1519.

2. Young FE, Nightingale SL, Temple RA. The Preliminary Report of the Findings of the Aspirin Component of the Ongoing Physicians’ Health Study: The FDA Perspective on Aspirin for the Primary Prevention of Myocardial Infarction. JAMA 1988; 259: 3158-60.

3. Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the Prevention of Cardiovascular Disease in Men: The Physicians’ Health Study II Randomized Controlled Trial. JAMA 2008; 300: 2123-33.

4. Gaziano JM, Glynn RJ, Christen WG, et al. Vitamins E and C in the Prevention of Prostate and Total Cancer in Men: The Physicians’ Health Study II Randomized Controlled Trial. JAMA 2009; 301: 52-62.

5. Cook NR, Lee I-Min, Gaziano JM, et al. Low-Dose Aspirin in the Primary Prevention of Cancer: The Women’s Health Study: A Randomized Controlled Trial. JAMA 2005; 294: 47-55.

6. Lee I-Min, Cook NR, Gaziano JM, et al. Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer: The Women’s Health Study: A Randomized Controlled Trial. JAMA 2005; 294: 56-65.

7. Forsythe M, Calnan M, Wall B. Doctors as patients: postal survey examining consultants and general practitioners adherence to guidelines. BMJ 1999; 319: 605-8.

8. Шальнова С.А., Оганов Р.Г., Деев А.Д., Кукушкин С.К. Здоровье российских врачей. Клинико-эпидемиологический анализ. Кардиоваск тер профил 2008; 6: 24-30.

9. Задионченко В. С., Ливандовский Ю.А. О состоянии здоровья врачей (результаты анкетирования). Врач 2004; 1: 58-60.

10. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24(1): 67-74.

11. European Guidelines on CVD Prevention in clinical practice. EHJ 2007; 24: 1601-10.

12. The Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. The. N Engl J Med 1989; 321: 129-35.

13. Lee I-M, Cook NR, Manson JE, et al. ß-Carotene Supplementation and Incidence of Cancer and Cardiovascular Disease: the Women’s Health Study. J Natl Cancer Inst. 1999; 91: 2102-6.

14. Левшин В.Ф., Н.И.Слепченко. Курение среди врачей и их готовность к оказанию помощи пациентам в отказе от курения. РМЖ 2009; 17(14): 917-20.

15. Meyers DG, Neuberger JS, He J. Cardiovascular effects of bans of smoking in public places: a systematic review and metaanalysis. JACC 2009; 54(14): 1249-55.

16. http://www.who.int/tobacco/en/atlas5.pdf

17. Барбараш О.Л., Башева Л.И., Смакотина С.А. и др. Факторы сердечно-сосудистого риска у врачей различных специальностей. Кардиология 2008; 7: 52-5.

18. Law MR, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomisedtrials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.

19. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009; 338: b2376.

20. Chobanian AV, Bakris GL, Black HR, et al. National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Hypertension 2003; 42: 1206-52.